Ivabradine

Phase 3Withdrawn

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heart Transplantation, Elevated Resting Heart Rate

Conditions

Heart Transplantation, Elevated Resting Heart Rate

Trial Timeline

Nov 2, 2018 → Feb 19, 2020

NCT ID

NCT03619187

About Ivabradine

Ivabradine is a phase 3 stage product being developed by Amgen for Heart Transplantation, Elevated Resting Heart Rate. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03619187. Target conditions include Heart Transplantation, Elevated Resting Heart Rate.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03619187	Phase 3	Withdrawn	Nov 2, 2018	Feb 19, 2020	Heart Transplantation, Elevated Resting Heart Rate
NCT03456856	Approved	Completed	Sep 28, 2017	May 20, 2019	Heart Failure (HF)
NCT02827500	Approved	Completed	Jul 1, 2016	Oct 15, 2018	Heart Failure

Competing Products

20 competing products in Heart Transplantation, Elevated Resting Heart Rate

See all competitors

Product	Company	Stage	Hype Score
IV diuretic	Nuwellis	Pre-clinical	15
IV Loop Diuretics	Nuwellis	Pre-clinical	15
Stepped pharmacologic care	Nuwellis	Phase 3	69
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	15
TRV120027 + Normal Saline	Trevena	Phase 1	25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	44
TRV120027 + Placebo	Trevena	Phase 1/2	33
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	44
INXN-4001	Precigen	Phase 1	28
LY3461767 + Placebo	Eli Lilly	Phase 1	33
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	85
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	52
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	85
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	77
Olmesartan	Daiichi Sankyo	Phase 3	77
Carperitide + Placebo	Daiichi Sankyo	Phase 2	52
Edoxaban	Daiichi Sankyo	Pre-clinical	23
Regadenoson	Astellas Pharma	Phase 1	33
Advagraf + Prograf	Astellas Pharma	Phase 2	52
FK506E	Astellas Pharma	Phase 3	77

Other Products from Amgen